TRCT
STSA

Tower Research Capital (TRC)’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Tower Research Capital (TRC)’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,280
Closed -$6K – 6549
2023
Q1 		$6K Buy
+8,280
New +$7.62K ﹤0.01% 4917
2022
Q4 		– Sell
-110
Closed -$1K – 6678
2022
Q3 		$1K Buy
+110
New +$624 ﹤0.01% 5934
2022
Q2 		– Sell
-1,782
Closed -$7K – 6822
2022
Q1 		$7K Buy
1,782
+1,590
+828% +$7.17K ﹤0.01% 4810
2021
Q4 		$1K Sell
192
-4,515
-96% -$22.9K ﹤0.01% 5975
2021
Q3 		$22K Buy
4,707
+2,206
+88% +$11.7K ﹤0.01% 3653
2021
Q2 		$18K Sell
2,501
-8,343
-77% -$45K ﹤0.01% 4018
2021
Q1 		$64K Buy
10,844
+2,391
+28% +$14.5K ﹤0.01% 2918
2020
Q4 		$39K Sell
8,453
-38,236
-82% -$165K ﹤0.01% 3356
2020
Q3 		$182K Buy
46,689
+45,276
+3,204% +$910K ﹤0.01% 2666
2020
Q2 		$41K Buy
+1,413
New +$32.7K ﹤0.01% 3218

Tower Research Capital (TRC)'s STSA Position: Q2 2023 in Review

Tower Research Capital (TRC) sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 8,280 shares — an estimated $6K sold.

Tower Research Capital (TRC) first reported a position in STSA in Q2 2020 and held it in 10 quarters. The position peaked at $182K in Q3 2020. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

  • Tower Research Capital (TRC) reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 8,280 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $6K.
  • Tower Research Capital (TRC) first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $182K in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2023, filed 14 Aug 2023.